Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-31
2005-05-31
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06900212
ABSTRACT:
1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the treatment of sub-type anxiety disorders chosen from the sub-types: panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia, and fibromyalgia. A preferred salts is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
REFERENCES:
patent: 5532241 (1996-07-01), Bottcher et al.
patent: 5723614 (1998-03-01), Bathe et al.
patent: WO 0006160 (1998-03-01), None
DSM-IV, Online Psychological Services, PsychologyNet.org, list of mental disorders, 1994, 1-3.*
Bartoszyk G D et al.: “EMD 68843, A Seritonin Reuptake Inhibitor with Selective Presynaptic 5-HT1A Receptor Agonistic Properties” European Journal Of Pharmacology, Amsterdan, NL, vol. 322, Mar. 1997, pp. 147-153, XP000917722 ISSN: 0014-2999.
Silverstone et al., “The Effects of Administration of mCPP on Psychological, Cognitive, Cardiovascular, Hormonal and MHPG Measurements in Human Volunteers” Int.Clin. Psychopharmacol(1994); 9: 173-178.
Pols et al., “Yohimbine Premedication and 35% CO2Vulnerability in Healthy Volunteers”Eur Arch Psychiatry Clin. Neurosci(1994); 244: 81-85.
Lesch, et al. “5-HT1AReceptor-effector System Responsivity in Panic Disorder”Psychopharmacology(1992); 106: 111-117.
Charney, et al., “Serotonin Function in Anxiety”Psychopharmacology(1987); 92: 14-24.
Pohl, et al., “Serotonergic Anxiolytics in the Treatment of Panic Disorder: A Controlled Study with Buspirone”Psychopathology(1989); 22 (suppl. 1):60-67.
Sheehan, et al., “The Relative Efficacy of High-dose Buspirone and Alprazolam in the Treatment of Panic Disorder: A Double-Blind Placebo-controlled Study”Acta Psychiatr Scand(1993); 88: 1-11.
Sheehnan, et al., “Is Buspirone Effective for Panic Disorder?”Journal of Clinical Psychopharmacology(1990); vol. 10, No. 1:3-11.
Napoliello, et al., Buspirone: A Worldwide UpdateBritish Journal of Psychiatry(1991); 159 (suppl. 12), 40-44.
Sànchez et al., “Effect of Serotonergic Drugs on Footshock-induced Ultrasonic Vocalization in Adult Male Rats”Behavioural Pharmacology(1993); 4, 269-277.
Bourin et al., Provactive Agents in Panic Disorder:Thérapie(1995); 50: 301-306.
Molewijk et al., “Conditioned Ultrasonic Distress Vocalizations in Adult Male Rats as a Behavioural Paradigm for Screening Anti-panic Drugs”Psychopharmacology(1995); 117: 32-40.
De Vry et al., “Shock-induced Ultrasonic Vocalization in Young Adult Rats: a Model for Testing Putative Anti-anxiety Drugs”Eur J. Pharmacol(1993); 249: 331-339.
Van Vliet et al., “Effects of the 5-HT1AReceptor Agonist Flesinoxan in Panic Disorder”Psychopharmacology(1996); 127: 174-180.
Cottraux, et al., “A Controlled Study of Cognitive Behaviour Therapy with Buspirone or Placebo in Panic Disorder with Agoraphobia”British Journal of Psychiatry(1995); 167, 635-641.
Zuardi, “5-HT-Related Drugs and Human Experimental Anxiety”Neuroscience&Biobehavioral Reviews,vol. 14, (1990); 507-510.
Kasper und Resinger, “Panic Disorder: the Place of Benzodiazepines and Selective Serotonin Reuptake Inhibitors”Eur Neuropsychopharmacol(2001); 11: 307-321.
Sànchez und Meier, “Behavioral Profiles of SSRIs in Animal Models of Depression, Anxiety and Aggression, Are they all alike?”Psychopharmacology(1997); 129:197-205.
Broocks et al., “Behavioral, Physiological and Neuroendocrine Respones in Healthy Volunteers to m-Chlorophenylpiperazine (m-CPP) with and without Ondansetron Pretreatment”Psychopharmacology(1997); 130: 91-103.
Sànchez et al., “Assesment of Relative Efficacies of 5-HT1ARecptor Ligands by Means of in Vivo Animal Models”Eur. J. Pharmacol(1996); 315: 245-254.
Seibyl et al., “Effects of Ritanserin on the Behavioral, Neuroendocrine, and Cardiovasular Responses to Meta-Chlorophenylpiperazine in Healthy Human Subjects”Psychiatry Res.(1991); 38: 227-236.
Broocks et al., “Increases Psychological Responses and Divergent Neuroendocrine Responses to m-CPP and Ipsapirone in Patients with Panic Disorder”Int Clin. Psychopharmacol(2000); 15: 153-161.
Bartoszyk Gerd
Boettcher Henning
Sedman Ewen
Seyfried Christoph
Von Amsterdam Christoph
Cook Rebecca
Merck Patent GmbH
Millen White Zelano & Branigan P.C.
LandOfFree
Use of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3413091